Entelexo is an early-stage biotechnology company that develops novel methods of engineering and manufacturing therapeutic exosomes. We have built a proprietary platform that allows us to rapidly prototype therapeutics with applications for a variety of autoimmune diseases. Entelexo’s technology addresses major manufacturing scalability and reproducibility challenges facing the newly expanding field of engineered exosome therapeutics by building a pipeline of products from a single universal base exosome. This technology enables drug candidate development in a fraction of the time it takes Big Pharma and other emerging competitors and streamlines regulatory filings.Entelexo exosomes have demonstrated the capacity to affect multiple types of cells simultaneously, potentially changing the way autoimmune diseases are treated. We have developed a pipeline of products that have been de-risked in preclinical studies and are targeting indications with a low barrier to market entry to achieve clinical validation quickly with their internal programs. We are also seeking partnerships to further develop our platform technology and disrupt some of the largest autoimmune disease markets.